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Background: Although venous thromboembolism (VTE) is a known common complication in 
cancer patients, there is limited knowledge on patient-related and cancer-specific risk factors in 
the general population. The Scandinavian Thrombosis and Cancer (STAC) Cohort was established 
by merging individual data from three large Scandinavian cohorts (The Tromsø Study, the second 
Nord-Trøndelag Health Study, and the Danish Diet, Cancer and Health Study). Here, we present 
the profile of the STAC cohort and provide age-specific incidence rates of VTE and cancer.
Methods: The STAC cohort includes 144,952 subjects aged 19–101 years without previous 
VTE or cancer. Baseline information collected in 1993–1997 included physical examination, 
self-administered questionnaires, and blood samples. Validated VTE events and cancer diagnoses 
were registered up to 2007–2012.
Results: There were 2,444 VTE events (1.4 per 1,000 person-years [PY]) during follow-up, and the 
incidence increased exponentially from 0.3 per 1,000 PY in subjects aged 20–29 years to 6.4 per 
1,000 PY in subjects aged 80+. Overall, 51% of the VTE events were provoked, and cancer was 
the most common provoking factor (19%), followed by immobilization and surgery (both 15%). 
In total, 19,757 subjects developed cancer during follow-up (9.8 per 1,000 PY), and the 5-year 
age-specific incidence rates of cancer were coherent with corresponding rates from the Norwegian 
Cancer Registry.
Conclusion: The STAC cohort will provide a unique opportunity to explore the epidemiology 
and impact of genetic and environmental patient-related and cancer-specific risk factors for 
VTE in the general population.
Keywords: venous thromboembolism, incidence rates, person-years, pulmonary embolism, 
population-based cohort, prospective, cancer
Introduction
Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pul-
monary embolism (PE), is a common complication and a predictor of poor survival in 
cancer patients.1 The reported annual incidence proportions of VTE in cancer patients 
vary substantially between 0.5% and 20%,2 and cancer is associated with 20%–25% 
of all incident VTE events.3–5 Thromboprophylaxis is not recommended to all cancer 
patients due to the heterogeneity of VTE risk in various cancer types.6 These consid-
erations emphasize the need to identify risk factors for cancer-related VTE in order to 
recognize high-risk patients who may benefit from thromboprophylaxis.
Discharge registries may represent large and valuable databases when exploring 
the risk of VTE in cancer patients. However, a recent Danish study reported that the 
positive predictive value of VTE discharge diagnoses was only 75%, indicating that the 
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registry data without any further VTE validation should be 
used with caution in medical research.7 We have established 
the Scandinavian Thrombosis and Cancer (STAC) Cohort, 
which is a large population-based cohort study, including 
individual data from three well-established prospective 
cohort studies in Norway and Denmark. These cohorts 
include thorough validation of symptomatic VTE events and 
the information regarding cancer exposure is obtained from 
complete national cancer registries.
The overall aim of the STAC cohort is to investigate the 
impact of cancer on the risk of VTE by exploring genetic and 
environmental patient-related and cancer-specific risk factors 
in order to identify high-risk patients who may benefit from 
thromboprophylaxis. Age-specific absolute and relative risks 
of VTE and related complications (mortality and recurrent 
VTE) in cancer patients will be calculated and compared with 
the general population. The risk will be assessed for overt 
and occult cancer, within various cancer sites, across cancer 
stages, across histologic grades, and at different time intervals 
after cancer diagnosis. The impact of established and novel 
genetic variants will be investigated by targeted gene sequenc-
ing in a large case–control study derived from STAC.
Here, we present the overall design and methods of the 
STAC cohort. We will also provide age-specific incidence 
rates (IRs) of VTE and cancer in the three cohorts and in 
the STAC cohort. The age-specific IRs of cancer in the 
STAC cohort will be compared with expected IRs based on 
data from the Cancer Registry of Norway.
Methods
study population
The STAC cohort includes individual data from three large 
population-based cohort studies with enrollment in 1993–1997, 
ie, the fourth survey of the Tromsø Study (Tromsø 4) in 
 Norway, the second Nord-Trøndelag Health (HUNT 2) Study 
in Norway, and the Diet, Cancer and Health (DCH) Study in 
Denmark.
The Tromsø Study8 consists of six health surveys con-
ducted in Tromsø, which is the largest city in Northern 
Norway (about 70,000 inhabitants). The Tromsø Study was 
established to investigate the epidemiology of cardiovascular 
diseases and a broad spectrum of other chronic diseases. In 
the Tromsø 4 Study, conducted in 1994–1995, all inhabit-
ants $25 years in the municipality of Tromsø were invited, 
of whom 27,158 attended (77% of the eligible population).
The HUNT Study9 has conducted three health surveys in 
the Nord-Trøndelag County, which is located geographically 
in the middle of Norway and includes six small towns 
(between 12,000 and 21,000 inhabitants) combined with 
sparsely populated rural areas. The HUNT 2 Study in 
1995–1997 was also designed to investigate cardiovascu-
lar disease and other chronic diseases in accordance with 
national health priorities. All residents $20 years of Nord-
Trøndelag County were invited of which 65,237 participated 
(69% of the eligible population).
The DCH Study10 was initiated in 1993–1997 and 
designed to investigate the associations between diet, life-
style factors, cancer, and other chronic diseases. In the DCH 
Study, all inhabitants aged 50–64 years, who were born in 
Denmark, living in the urban areas of Copenhagen and Aar-
hus, and without a previous diagnosis of cancer registered 
in the Danish Cancer Registry were invited, of whom 57,054 
participated (35% of those invited).
In the two Norwegian cohorts, subjects with a cancer 
diagnosis (registered in the Norwegian Cancer Registry) prior 
to enrollment were excluded before merging the three cohorts. 
Moreover, subjects with known VTE prior to baseline were 
excluded in all cohorts prior to merging. In the DCH Study, 
discharge diagnoses were used as basis for exclusions of sub-
jects with prior VTE, whereas in the two Norwegian cohorts, 
subjects with prior VTE were detected through the medical 
records review. After merging, the study population counted 
144,952 subjects aged 19–101 years who were followed from 
the date of inclusion (1993–1997) to the end of follow-up 
(2007–2012). Figure 1 summarizes the number of invited and 
the number of subjects who attended in the three cohorts and 
the total number of participants in the STAC cohort.
All included study participants gave their informed writ-
ten consent, and respective regional committees for research 
ethics in Norway and Denmark approved the cohort studies 
and the collaboration study.
Baseline measurements
Baseline information was obtained by physical examina-
tion, self-administered questionnaires, and nonfasting blood 
 samples. Height and weight were measured with light cloth-
ing and without shoes, and body mass index was calculated as 
weight in kilograms divided by the height in meters squared 
(kg/m2). Trained personnel recorded blood pressure using an 
automatic device. Three measurements were performed after 
2 minutes at rest in the Tromsø 4 Study and the HUNT 2 
Study, and the average of the two last readings were chosen. 
In the DCH Study, blood pressure was measured twice after 
5 minutes at rest, and the lowest reading was used.
Information regarding education level, smoking hab-
its (never/former/current and duration in years), alcohol 
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 consumption (units per week), physical activity, diabetes 
mellitus, and use of antihypertensives was collected from the 
self-administered questionnaires. The level of education was 
categorized into basic schooling (7–10 years), upper second-
ary education (high school/vocational school), and tertiary 
education (college/university). In the STAC cohort, hard 
physical activity was defined as equal to or more than 1 hour 
of sports/physical activity per week that caused sweating 
or breathlessness. Detailed information about the baseline 
variables in each cohort is described elsewhere.8–10
Identification and validation  
of cancer diagnosis
Cancer registration is mandatory by law in both Norway 
and Denmark. Individual data from the three cohorts were 
linked to the Norwegian and Danish cancer registries by the 
use of the unique national civil registration number, which 
is assigned to every Norwegian and Danish citizen at birth. 
The obtained information included date of cancer diagnosis, 
location of the disease (ICD10 codes C00-96), histological 
grade (ICO-3), and cancer stage (localized, regional, distant, 
or unknown). Subjects with nonmelanoma skin cancers 
(ICD10 C44) were regarded as cancer-free. Both cancer 
registries are considered complete and valid, and evaluations 
have reported 98.8% completeness in Norway and 95%–98% 
in Denmark, with 94% and 93% microscopically confirmed 
diagnoses, respectively.11,12
Identification and validation  
of venous thromboembolic events
Only first time, objectively confirmed symptomatic VTE 
events have been included in the STAC cohort. Trained per-
sonnel have reviewed the medical records for each potential 
case of VTE in all three included cohorts, and both inpatients 
and outpatients have been included.
In the Tromsø 4 Study,13 VTE events during follow-up 
were identified by searching the hospital discharge diagnosis 
registry, the radiology procedure registry, and the autopsy 
registry at the University Hospital of North Norway, which 
is the only hospital serving the municipality of Tromsø. The 
four validation criteria were symptomatic VTE combined 
with objective confirmatory tests (ultrasound, venography, 
computed tomography (CT) scan, perfusion–ventilation 
scan, pulmonary angiography, or autopsy), which resulted 
in a VTE diagnosis that required treatment.
In the HUNT 2 Study, a VTE endpoint registry, the TROL 
Study was established.14 VTE events during follow-up were 
identified by the use of the hospital discharge diagnosis 
Invited (n): 37,558
Participated (n): 27,158
Attendance rate*: 77%
Age: 25–97 years
Invited (n): 93,898
Participated (n): 65,237
Attendance rate*: 69%
Age: 19–103 years
Invited (n): 160,725
Participated (n): 57,053
Attendance rate: 35%
Age: 50–64 years
Excluded prior to merging:
previous cancer and VTE
Included: 144,952
Age: 19–101 years
HUNT 29 (1995–1997) DCH10 (1993–1997)Troms∅ 48 (1994–1995)
STAC COHORT (1993–1997)
Figure 1 The sTaC cohort.
Note: *% of eligible population.
Abbreviations: sTaC, scandinavian Thrombosis and Cancer; DCh, Danish Diet, Cancer and health study; hUnT 2, second nord-Trøndelag health study, VTE, venous 
thromboembolism.
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registry and the radiology procedure registry at the two local 
hospitals (Levanger and Namsos in Nord-Trøndelag County, 
Norway) and at the tertiary-care center of the region, St Olav’s 
Hospital. The validation criteria included symptomatic VTE 
events that required treatment and confirmation by objec-
tive diagnostic tests (ultrasound, venography, CT scan, or 
perfusion–ventilation scan).
In the DCH Study,15 incident VTE events were found by the 
use of the participants’ civil registration numbers and linkage to 
the Danish National Patient Registry and the Danish National 
Death Registry. A verified VTE diagnosis required typical 
clinical symptoms combined with a confirmatory diagnostic 
test (ultrasound, venography, CT-scan, perfusion–ventilation 
scan, echocardiography, or autopsy). Detailed information 
on the identification and validation of the VTE events in each 
cohort study has been previously described.13–15
The VTE events in all three cohorts were classified as 
DVT or PE, and concurrent DVT and PE were registered 
as PE. The VTE events were further classified as provoked 
and unprovoked VTE. A provoked event in the STAC cohort 
required that one or more of the following provoking fac-
tors were present: overt cancer at the time of the VTE event, 
recent trauma or surgery, marked immobilization, travel, 
acute medical condition, or other risk factors described by 
the physician in the medical record such as intravascular 
catheters. There were some differences in the definitions 
of provoking factors in the three included cohorts.7,13,14 
Provoking factors were registered up to 8 weeks prior to 
the VTE event in the Tromsø Study, while it was registered 
up to 3 months ahead of the event in the other two studies. 
Additionally, the minimum duration of the travel variable 
defined to be a provoking factor varied between 4 and 8 hours 
in the three cohorts. Furthermore, the HUNT 2 Study did 
not include acute medical conditions as individual factors, 
but instead registered prolonged bed rest (immobility) due 
to acute medical conditions. The acute medical conditions 
included in both the Tromsø 4 Study and the DCH Study 
were stroke, acute myocardial infarction, and infection, while 
the DCH Study also included exacerbation of chronic lung 
disease and activity in collagenous disease.
study design
In our prospective cohort, all participants were followed up 
from the date of inclusion in 1993–1997 to the date of death, 
migration, or end of follow-up for VTE, and cancer registration 
in the respective cohorts. Incident VTE events were identified 
until December 31, 2012 in Tromsø 4, December 31, 2007 in 
HUNT 2, and April 30, 2008 in DCH. Cancer  diagnoses were 
registered up to December 31, 2012 in Tromsø 4 and DCH 
and to December 31, 2009 in HUNT 2. Information regarding 
date of migration and death were obtained by linkage of the 
national civil registration numbers to the Central Population 
Registers in Norway and Denmark.
When comparing studies regarding the risk of VTE in 
cancer patients, heterogeneity in the follow-up time is a meth-
odological challenge, and it is recommended that follow-up 
should preferably start at the time of cancer diagnosis.1 In the 
STAC cohort, subjects with cancer or VTE prior to enroll-
ment were excluded. Consequently, all individuals started to 
accrue nonexposed person–time in the beginning of the study 
period. Individuals who developed cancer during follow-up 
changed their exposure status and started to accrue cancer-
exposed observational time from the date of cancer diagnosis. 
Thus, individuals who developed cancer contributed to both 
nonexposed and cancer-exposed person-years (PY) at risk 
during the study period. The design of the STAC cohort also 
facilitated an observational time with occult cancer exposure, 
which is particularly interesting as VTE risk during this 
period is not influenced by cancer treatment, a well-known 
risk factor for cancer-related VTE.1 Figure 2 illustrates the 
potential observational times.
statistical analyses
Descriptive characteristics of the study population and the 
VTE events were presented within each cohort as means with 
No cancer
No cancer Occult cancer Overt cancer
Time (years)
S
u
b
je
ct
 
A
B
Figure 2 Potential observational periods in the sTaC cohort.
Notes: (A) a person who did not develop cancer during follow-up contributed 
person time at risk of VTE in the noncancer exposed category during the entire 
study period; (B) a person who developed cancer during follow-up would contribute 
with person time at risk of VTE in three different categories during the study period: 
(i) the noncancer exposed, (ii) the occult cancer exposed (starting 1 year before the 
cancer was diagnosed), and (iii) the overt cancer exposed starting from the date of 
cancer diagnosis.
Abbreviations: sTaC, scandinavian Thrombosis and Cancer; VTE, venous throm-
boembolism.
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5–95% ranges for normally distributed continuous variables, 
and as medians with 25–75% ranges for continuous variables 
with skewed distribution. Ten-year age-specific IRs of VTE 
and cancer with 95% confidence intervals (CIs) were cal-
culated as numbers of events per 1,000 PY at risk. In these 
analyses, the subjects contributed with PY into different age 
groups, as they were aging during follow-up.
For overall cancer in the STAC cohort, we calculated 
5-year age-specific IRs per 1,000 PY in women and men 
for the period 1998–2009 and compared these figures 
graphically with corresponding IRs in the Norwegian Cancer 
Registry. This period was chosen because it included com-
plete follow-up of cancer for all the three included cohorts. 
 Statistical analyses were performed with STATA version 13.0 
(Stata Corporation, College Station, Texas, USA).
Results
The distribution of baseline characteristics in the three 
included cohorts and in the merged STAC cohort is presented 
in Table 1. Median age at inclusion was highest in the DCH 
Study, followed by the HUNT 2 Study and the Tromsø 4 
Study (56 years, 48 years, and 45 years, respectively). The 
proportion of women was slightly higher in the STAC cohort 
(52.6% vs 47.4%, respectively) as well as in the three cohorts 
separately. In the DCH Study, the proportion of subjects with 
low education (basic school) was lower than in the Tromsø 
4 Study and HUNT 2 Study (14.9%, 33.9%, and 34.2%, 
respectively). It has been reported that subjects with basic 
school as highest completed education are underrepresented 
in the DCH Study.10 However, subjects with basic school 
as highest completed education represent 26.7% of the 
Table 1 Baseline characteristics obtained in 1993–1997 within the separate cohorts and in the merged sTaC cohort
Tromsø 4 HUNT 2 DCH STAC
subjects (n) 26,093 62,846 56,013 144,952
age (years)a 45 (35–57) 48 (36–63) 56 (53–60) 53 (43–61)
sex
 Men 47.7 (12,438) 47.0 (29,538) 47.6 (26,674) 47.4 (68,650)
 Women 52.3 (13,655) 53.0 (33,308) 52.4 (29,339) 52.6 (76,302)
Questionnaire data
Education
 Basic school 33.9 (8,852) 34.2 (21,471) 14.9 (8,318) 26.7 (38,641)
 high school 35.9 (9,366) 41.6 (26,153) 62.7 (35,130) 48.7 (70,649)
 College/University 29.8 (7,780) 19.1 (11,995) 22.1 (12,375) 22.2 (32,150)
 Missing 0.4 (95) 5.1 (3,227) 0.3 (190) 2.4 (3,512)
hard physical activity
 $1 hour per week 30.5 (7,948) 24.5 (15,389) 31.7 (17,736) 28.3 (41,073)
 Missing ,0.1 (22) 10.3 (6,462) 0.1 (75) 4.5 (6,559)
smoking
 never 36.0 (9,399) 44.6 (28,009) 35.1 (19,633) 39.4 (57,041)
 Former 26.6 (6,947) 20.4 (12,827) 28.8 (16,116) 24.8 (35,890)
 Current ,15 cigarettes 24.5 (6,401) 20.4 (12,825) 13.1 (7,342) 18.3 (26,568)
 Current 15–25 cigarettes 10.7 (2,789) 6.7 (4,231) 16.1 (9,030) 11.1 (16,050)
 Current 25+ cigarettes 2.0 (509) 2.2 (1,357) 6.9 (3,857) 3.9 (5,723)
 Missing 0.2 (48) 5.7 (3,597) 0.6 (35) 2.5 (3,680)
smoke time (years)a,b 20 (12–30) 20 (11–30) 32 (20–39) 25 (14–35)
 Missing 0.5 (88) 11.1 (3,483) 0.7 (272) 4.4 (3,843)
alcohol units/weeka 1 (0–3) 1 (0–2) 8 (3–18) 2 (1–7)
 Missing 0.8 (197) 12.8 (8,027) ,0.1 (3) 5.7 (8,227)
self-reported diabetes 1.7 (452) 2.9 (1,794) 2.1 (1,175) 2.4 (3,421)
Use of antihypertensives 6.0 (1,575) 10.7 (6,718) 12.3 (6,868) 10.5 (15,161)
Health examination
 systolic blood pressure (mmhg) 134 (109–175) 137 (109–179) 140 (109–176) 137 (109–177)
 Diastolic blood pressure (mmhg) 78 (60–100) 80 (62–102) 83 (67–101) 81 (63–101)
 height (cm) 170 (155–186) 170 (156–186) 170 (156–185) 170 (156–185)
 Weight (kg) 73 (53–97) 76 (56–101) 76 (55–100) 75 (55–100)
 Body mass index (kg/m2) 25.2 (19.9–32) 25.8 (20.6–33.7) 26.0 (20.4–33.3) 26.0 (20.4–33.3)
Notes: Values are percentages with absolute numbers in parentheses or means with 5%–95% ranges, except fora. aValues are medians with 25–75% ranges due to skewed 
distribution of data. The proportion of missing is not reported for variables that contain less than 2% missing. bsmoke time is reported for smokers only (previous and 
current), and the missing proportion is among smokers.
Abbreviations: sTaC, scandinavian Thrombosis and Cancer; DCh, Danish Diet, Cancer and health study; hUnT 2, second nord-Trøndelag health study.
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participants in the STAC cohort due to the higher proportion 
of subjects with low education in the Norwegian studies. In 
coherence with reported differences in alcohol consumption 
between Norway and Denmark,16 participants in the DCH 
Study had substantially higher weekly alcohol consumption 
than the Norwegian participants. Participants in the HUNT 2 
Study had the highest proportion of nonsmokers. The systolic 
and diastolic blood pressure and the use of antihypertensives 
increased with advancing median age in the cohorts.
Characteristics of patients with VTE by study origin 
are shown in Table 2. The proportion of provoked VTE 
was slightly higher in the Tromsø 4 Study (55.1%) than 
in the DCH Study and HUNT 2 Study (50.1% and 48.0%, 
respectively). In the STAC cohort, 51% of the VTE events 
Table 2 Characteristics of patients with VTE events at the time of VTE diagnosis within the separate cohorts and in the merged sTaC 
cohort
Tromsø 4 HUNT 2 DCH STAC
subjects with VTE 664 989 791 2,444
age at VTE diagnosis 69 (44–88) 69 (41–88) 65 (56–74) 68 (45–87)
sex (men) 46.7 (310) 47.9 (474) 56.4 (446) 50.3 (1,230)
VTE type
 PEa 42.8 (284) 38.7 (383) 41.2 (326) 40.6 (993)
 DVTa 57.2 (380) 61.3 (606) 54.5 (431) 58.0 (1,417)
 Unprovoked VTEb 44.9 (298) 52.0 (514) 49.9 (367) 49.4 (1,179)
 Provoked VTEb 55.1 (366) 48.0 (475) 50.1 (369) 50.6 (1,210)
Provoking factorsb
 Overt cancer 22.9 (152) 15.7 (155) 19.7 (156) 18.9 (463)
 surgery 14.3 (95) 17.1 (169) 11.4 (84) 14.6 (348)
 Trauma 7.7 (51) 10.4 (103) 0 6.4 (154)
 acute medical condition 14.3 (95) n/a 10.2 (75) 7.1 (170)
 immobilization 17.6 (117) 16.3 (161) 11.1 (82) 15.1 (360)
 Travel 0.9 (6) 2.5 (25) 5.7 (42) 3.1 (73)
 Other factor 5.1 (34) 5.4 (53) 5.7 (42) 4.1 (129)
Notes: Values are percentages with absolute numbers in parentheses or mean with 5–95% ranges in parentheses. aThere are 34 subjects in the DCh study with missing 
information for PE and DVT; bseveral subjects have more than one provoking factor. The given percentages of unprovoked VTE, provoked VTE, and each provoking factor 
are among total VTE events in each study with exclusion of 55 events with missing information on provoking factors in the DCh study.
Abbreviations: sTaC, scandinavian Thrombosis and Cancer; DCh, Danish Diet, Cancer and health study; hUnT 2, second nord-Trøndelag health study; VTE, venous 
thromboembolism; DVT, deep venous thrombosis; PE, pulmonary embolism; n/a, not applicable.
Table 3 Age-specific IRs of VTE per 1,000 PY with 95% confidence intervals within the separate cohorts and in the merged STAC 
cohort
Age (years) Tromsø 4 HUNT 2 DCH STAC
PY Events IR PY Events IR PY Events IR PY Events IR
20–29 6,648 1 0.2 (0.02–1.1) 39,515 12 0.3 (0.2–0.5) n/a n/a n/a 46,163 13 0.3 (0.2–0.5)
30–39 55,087 17 0.3 (0.2–0.5) 105,397 35 0.3 (0.2–0.5) n/a n/a n/a 160,484 52 0.3 (0.2–0.4)
40–49 99,147 46 0.5 (0.3–0.6) 137,592 78 0.6 (0.5–0.7) n/a n/a n/a 236,739 124 0.5 (0.4–0.6)
50–59 96,481 118 1.2 (1.0–1.5) 141,081 127 0.9 (0.8–1.1) 221,503 153 0.7 (0.6–0.8) 459,064 398 0.9 (0.8–1.0)
60–69 65,749 139 2.1 (1.8–2.5) 101,471 176 1.7 (1.5–2.0) 359,362 480 1.3 (1.2–1.5) 526,582 795 1.5 (1.4–1.6)
70–79 40,241 179 4.4 (3.8–5.2) 83,773 299 3.6 (3.2–4.0) 69,888 158 2.3 (1.9–2.6) 193,903 636 3.3 (3.0–3.5)
80+ 20,342 164 8.1 (6.9–9.4) 45,779 262 5.7 (5.1–6.5) n/a n/a n/a 66,121 426 6.4 (5.9–7.1)
Total 383,695 664 1.7 (1.6–1.9) 654,609 989 1.5 (1.4–1.6) 650,753 791 1.2 (1.1–1.3) 1,689,056 2,444 1.4 (1.4–1.5)
Notes: subjects contributed PYs within different age groups while aging during follow-up. age at the time of VTE diagnosis was registered for the VTE events.
Abbreviations: irs, incidence rates; PY, person-years; sTaC, scandinavian Thrombosis and Cancer; VTE, venous thromboembolism; PE, pulmonary embolism; DCh, 
Danish Diet, Cancer and health study; hUnT 2, second nord-Trøndelag health study; n/a, not applicable.
were provoked, whereas 49% were unprovoked. Cancer was 
the most common provoking factor in the STAC cohort and 
is associated with 18.9% of all the VTE events, followed by 
immobilization (15.1%) and surgery (14.6%).
Because the age distributions differed between the 
included cohorts, we estimated 10-year age-specific IRs of 
VTE per 1,000 PY in order to enable comparisons between 
the cohorts (Table 3). There were 2,444 VTE events dur-
ing a median follow-up of 11.7 years and the incidence 
increased with age for all cohorts. In the STAC cohort, the 
overall incidence of VTE was 1.4 per 1,000 PY and the 
incidence increased from 0.3 per 1,000 PY in subjects aged 
20–29 years to 6.4 per 1,000 PY in subjects above 80 years. 
In general, overall and age-specific IRs of VTE were highest 
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in the Tromsø 4 Study, followed by the HUNT 2 Study and 
the DCH Study.
Table 4 presents 10-year age-specific IRs of cancer per 
1,000 PY. In total, 19,757 incident cancers were detected 
during a median follow-up of 14.1 years (9.8 per 1,000 PY), 
and the incidence increased with age, as expected, for 
all cohorts. The age-specific cancer rates were approxi-
mately similar in the three included cohorts, except for a 
higher incidence among subjects aged 50–59 years in the 
DCH Study.
The distribution of selected cancer sites within each 
cohort is shown in Figure 3. Prostate, breast, colorectal, and 
lung were the most common cancers in all cohorts, account-
ing for 53%–61% of the cancer diagnoses. Breast cancer 
constituted 17.8% of all cancer diagnoses in the DCH Study, 
while the corresponding percentages in the Tromsø 4 Study 
and the HUNT 2 Study were 12.2% and 11.6%, respectively. 
The 10-year age-specific IRs of breast cancer were higher 
in the DCH Study than in the Norwegian studies (data not 
shown).
Figure 4 shows 5-year age-specific IRs of overall can-
cer per 1,000 PY for women and men in the STAC cohort 
between 1998 and 2009 compared to the corresponding rates 
given by the Norwegian Cancer Registry in the same time 
period. The age-specific IRs of cancers in women and men 
in the STAC cohort are similar to national figures.
Discussion
We have established a large population-based cohort study 
with validated VTE and cancer events to investigate the risk 
of VTE in cancer patients.
In accordance with previously reported IRs in adult 
populations in the developed countries4,17,18 and the reported 
impact of age,19,20 we found an overall IR of VTE in the STAC 
cohort of 1.4 per 1,000 years and an exponential increase at 
higher ages. The overall and 10-year age-specific IRs of VTE 
were highest in the Tromsø 4 Study, followed by the HUNT 
2 Study, and finally the DCH Study. This may be explained 
by the 5-year longer follow-up time of VTE in the Tromsø 
Study, along with the most comprehensive procedure to 
identify VTE events.
Definitions of provoking factors varied somewhat between 
the three cohorts, but in spite of this, the proportion of provoked 
VTE events was approximately 50% in all studies, which is 
in accordance with previous population-based studies.4,5 The 
proportion of provoked VTEs in a given study will clearly 
depend on the definition of included provoking factors, and a 
definite definition does not exist. For instance, the Tromsø 4 T
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HUNT 2 Study did not include acute medical conditions and 
the DCH Study registered trauma-related VTEs, but found no 
events. Nevertheless, since the overall proportion of provoked 
VTEs was quite similar in the included cohorts, we regard 
the STAC cohort suitable for future analyses differentiating 
between provoked and unprovoked VTE events.
The incidence of cancer increased similarly with age in all 
cohorts. The proportion of breast cancer, however, was higher 
in the DCH Study than in the Norwegian cohorts. The IR of 
breast cancer is higher in Denmark than in Norway and Copen-
hagen, where the majority of DCH participants are recruited 
from, has particularly high IRs.21 The DCH population has 
higher alcohol consumption and a lower proportion of subjects 
with basic school as their highest education level than the Nor-
wegian cohorts. Interestingly, higher risk of breast cancer in 
women from the Copenhagen area was recently reported to be 
related to higher education level and suggested to be attributed 
to differences in alcohol consumption, reproductive patterns, 
and use of hormone therapy.22 Similar results have been found 
in a Norwegian study including 93,638 women.23
Age-specific IRs of cancer in the STAC cohort were 
similar to corresponding IRs from the Cancer Registry of 
Norway. The attendance rates in the Tromsø 4 Study and 
HUNT 2 Study were high (77% and 69%, respectively), 
while the DCH had a low rate of 35%. Even though it has 
been reported that subjects with lower socioeconomic posi-
tions were under represented in the DCH Study, the age-
standardized IRs of cancer were not significantly different 
from the general Danish population.10
The main strengths of the STAC cohort are the prospec-
tive design with data from three large, well-established 
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Study had a slightly higher proportion of provoked VTEs 
(55%), presumably because both acute medical conditions and 
trauma were registered as provoking factors. Conversely, the 
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cohort studies, characterized by wide age distribution, long 
follow-up and detailed information on cancer exposure, VTE 
events, and confounders. The cancer events were obtained 
by linkage to complete cancer registries, and trained per-
sonnel confirmed all the VTE events according to objective 
criteria after a comprehensive identification process where 
different patient registries were examined. Some limitations 
merit consideration. We did not have verified informa-
tion on previous history of VTE among all participants in 
the Norwegian cohorts. In these cohorts, individuals who 
were excluded owing to prior VTE were detected through 
the medical records review, and the majority of these had a 
recurrent episode during the study period. Hence, some of 
the subjects who were treated as healthy participants during 
follow-up could be prevalent VTE cases who should have 
been excluded. In the DCH Study, discharge diagnoses were 
used as basis for exclusions of subjects with prior VTE and 
may have led to some misclassifications. However, this would 
only lead to a small change in overall number of PY in the 
STAC cohort, and thus would presumably have a negligible 
influence on the IRs of VTE. The DCH Study did not search 
the radiology procedure registry for VTE events, which 
may have slightly underestimated the incidence of VTE in 
the DCH and hence in the STAC cohort. Differences in the 
follow-up time may also have influenced the overall risk of 
VTE and cancer in the three included cohorts. Harmonization 
of baseline variables, such as physical activity and education, 
had some methodological challenges due to different ques-
tionnaires in Norway and Denmark, which may have resulted 
in some imprecisions in these variables. Another limitation is 
that we do not have access to measured biomarkers in blood 
(hemoglobin, platelet count, leukocyte count, etc) from all 
cohorts at baseline or during follow-up. Information about 
cancer treatment (ie, radiation and chemotherapy) is also lim-
ited and restricted to data from the national cancer registries. 
Finally, information on lifestyle factors was only assessed at 
baseline and may have changed over time, and hence resulted 
in some nondifferential misclassifications.
We have established a large Scandinavian cohort, includ-
ing individual data from three established population-based 
cohorts, the STAC cohort that will provide a unique oppor-
tunity to explore the impact of genetic and environmental 
risk factors, gene–environmental interactions, and cancer-
specific characteristics on the risk of cancer-related VTE in 
the general population.
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